Gaissmaier Christoph, Koh Jason L, Weise Kuno, Mollenhauer Juergen A
BG-Trauma Center, Eberhard-Karls-University, Schnarrenbergstrasse 95, Tübingen, Germany.
Injury. 2008 Apr;39 Suppl 1:S114-20. doi: 10.1016/j.injury.2008.01.033.
Extrapolating from the current state of the art in cartilage repair technology and basic science, we describe the future of regenerative medicine in the musculoskeletal system. Crucial milestones that have been recognized include supply with competent cells from autologous to xenogeneic sources, "intelligent" or "reactive" scaffold design, optimised application of humoral factors and the introduction of advanced gene-engineering technology. Besides these technical goals, ethical and legal considerations may significantly change the way pharmacological and medical components are recruited and regulated. At the same time, governmental regulatory bodies will have to accept new realities such as the existence of adaptive medical devices and of biological combination implants that are anywhere between a drug and a transplanted organ. For cartilage replacement itself, optimism seems to be justified regarding major advances within the next decade.
基于软骨修复技术和基础科学的当前发展水平进行推断,我们描述了肌肉骨骼系统再生医学的未来。已被认可的关键里程碑包括从自体到异种来源提供有能力的细胞、“智能”或“反应性”支架设计、体液因子的优化应用以及先进基因工程技术的引入。除了这些技术目标外,伦理和法律考量可能会显著改变药物和医疗组件的获取与监管方式。与此同时,政府监管机构将不得不接受新的现实,比如适应性医疗设备以及介于药物和移植器官之间的生物组合植入物的存在。对于软骨置换本身而言,在未来十年内取得重大进展似乎是有理由保持乐观的。